US Food and Drug Administration (FDA) has approved the cobas HPV (Human Papillomavirus) Test which identifies women at highest risk for developing cervical cancer. This test will help physicians make early, more accurate decisions about patient care, which may prevent many women from developing this deadly disease. Continue reading “FDA Approves Roche’s HPV Test for Identifying Women at Highest Risk for Cervical Cancer”
Bacteria have evolved complex mechanisms called quorum sensing systems that provide for cell-to-cell communication, an adaptation that allows them to wait until their population grows large enough before mounting an attack on a host or competing for nutrients. Lianhong Sun, a chemical engineer at the University of Massachusetts Amherst, has engineered one of these systems to create genetic switches that could lower the cost of producing therapeutic proteins and pharmaceuticals.
Continue reading “Newly Engineered Genetic Switches Enhance Production Of Proteins, Pharmaceuticals”
The first clinical studies of an experimental drug have revealed that obese people who take it for 12 weeks lose weight, even at very low doses. Short-term studies also suggest that the drug, called taranabant—the second drug designed to fight obesity by blocking cannabinoid receptors in the brain—causes people to consume fewer calories and burn more, researchers report in the January issue of Cell Metabolism, a publication of Cell Press. Cannabinoid receptors are responsible for the psychological effects of marijuana (Cannabis sativa), and natural “endocannabinoids” are important regulators of energy balance.
Oregon Health & Science University researchers have figured out how to turn a mouse into a factory for human liver cells that can be used to test how pharmaceuticals are metabolized.
The technique, published in the journal Nature Biotechnology, could soon become the gold standard not only for examining drug metabolism in the liver, which helps scientists determine a drug’s toxicity. But it also can be used as a platform for testing new therapies against infectious diseases that attack the liver, such as hepatitis C and malaria.
Two new studies show that a new drug called Cimzia may ease symptoms of Crohn’s disease.
Cimzia hasn’t been approved by the FDA yet. Patients would give themselves injections of the drug, which targets an inflammatory chemical called tumor necrosis factor (TNF) alpha.
The two new studies, published in The New England Journal of Medicine, highlight Cimzia’s clinical trials in Crohn’s disease patients.
Read rest of this article at WebMD site.
With ethical issues concerning use of discarded embryos and technical problems hindering development of stem cell therapies, scientists in Korea are reporting the first successful use of a drug-like molecule to transform human muscle cells into nerve cells. Their report, scheduled for the August 8 issue of the Journal of the American Chemical Society, a weekly journal, states that the advance could lead to new treatments for stroke, Alzheimer’s disease, Parkinson’s disease and other neurological disorders.
MIT researchers have developed a model that could predict how cells will respond to targeted drug therapies. Models based on this approach could help doctors make better treatment choices for individual patients, who often respond differently to the same drug, and could help drug developers identify the ideal compounds on which to focus their research.
In addition, the model could help test the effectiveness of drugs for a wide range of diseases, including various kinds of cancer, arthritis and immune system disorders, according to Douglas Lauffenburger, MIT professor of biological engineering and head of the department. Lauffenburger is senior author of a paper on the new model that will appear in the Aug. 2 issue of Nature.